glp-1 semaglutide weight loss for GLP-1 drugs, originally developed to

There is a reduction in myeloid-derived suppressor cells and pro-tumor proteins within the TME [186]

[6] It can attenuate neuroinflammation and promote neuroprotection in multiple sclerosis , inhibit microglial activation, and may enhance remyelination processes, thereby potentially decreasing relapse rates and neurological damage

Adverse events reported in the first few weeks were generally mild to moderate, and their incidence tended to lessen as dosing escalated and subjects adapted

While still in early days, they offer a complementary avenue to directly CNS-targeted therapies like monoclonal antibodies or neurotrophic drugs

[ 15 N 13 ]-CNCbl was prepared in-house as previously described [8]

Wauters L, Vanuytsel T